Anti CD146, MUC18 Biosimilar – Anti-CD146, MUC18 mAb – Research Grade

Description of Anti CD146, MUC18 Biosimilar - Anti-CD146, MUC18 mAb - Research Grade

Introduction

Anti CD146, also known as MUC18, is a cell surface glycoprotein that belongs to the immunoglobulin superfamily. It is highly expressed on the surface of endothelial cells, pericytes, and activated T cells. CD146 has been identified as a potential therapeutic target for various diseases, including cancer, inflammation, and autoimmune disorders.

Structure of Anti CD146, MUC18

Anti CD146, MUC18 is a monoclonal antibody (mAb) that specifically binds to CD146 on the surface of cells. It is a large protein with a molecular weight of approximately 130 kDa. The antibody is composed of two heavy chains and two light chains, which are linked together by disulfide bonds. The heavy chains are further divided into four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH). Similarly, the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for the specificity of the antibody, as they bind to the target antigen.

Activity of Anti CD146, MUC18

Anti CD146, MUC18 mAb has been shown to have multiple activities, including blocking the interaction between CD146 and its ligands, inhibiting cell proliferation and migration, and inducing cell death. CD146 is known to interact with various proteins, such as integrins, which play a crucial role in cell adhesion and migration. By blocking this interaction, Anti CD146, MUC18 mAb can inhibit the proliferation and migration of cells. Additionally, the antibody has been shown to induce cell death in cancer cells by activating cell death pathways.

Application of Anti CD146, MUC18

Anti CD146, MUC18 mAb has been extensively studied for its potential therapeutic applications. It has been shown to have promising results in the treatment of various diseases, including cancer, inflammation, and autoimmune disorders.

Cancer

CD146 is highly expressed in various types of cancer, including melanoma, breast cancer, and lung cancer. Anti CD146, MUC18 mAb has been shown to inhibit the growth and metastasis of these cancers by blocking the interaction between CD146 and its ligands. It has also been found to sensitize cancer cells to chemotherapy and radiotherapy, making it a potential adjuvant therapy for cancer treatment.

Inflammation

CD146 is also involved in the inflammatory response, and its overexpression has been linked to chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. Anti CD146, MUC18 mAb has been shown to reduce inflammation by inhibiting the migration of immune cells to the site of inflammation. It has also been found to decrease the production of pro-inflammatory cytokines, making it a potential therapy for inflammatory diseases.

Autoimmune disorders

CD146 has been identified as a potential target in autoimmune disorders, such as multiple sclerosis and systemic lupus erythematosus. Anti CD146, MUC18 mAb has been shown to inhibit the activation and proliferation of autoreactive T cells, which are responsible for the development of autoimmune diseases. It has also been found to decrease the production of autoantibodies, making it a potential therapy for autoimmune disorders.

Research Grade Anti CD146, MUC18 mAb

Anti CD146, MUC18 mAb is available in research grade for use in various laboratory experiments. It can be used for in vitro studies to investigate the role of CD146 in different cellular processes. The antibody can also be used for in vivo studies in animal models to evaluate its therapeutic potential in various diseases. Additionally, research grade Anti CD146, MUC18 mAb can be used for the development of diagnostic assays for the detection of CD146 in patient samples.

Conclusion In summary, Anti CD146, MUC18 mAb is a monoclonal antibody